Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study
A phase 2 trial of Osimertinib in advanced solid tumours, run by AstraZeneca, now recruiting.
Overview
Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study is a phase 2 interventional study registered as NCT07295821 by AstraZeneca, with 60 participants planned, started 2026-04-01 and due to reach its primary completion in 2029-05-30. Interventions recorded: Osimertinib.
Similar pages
not linked directly; found by shared links- TrialA Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)
Shares Osimertinib, AstraZeneca and the tag pipeline.
- TrialRoll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T)
Shares Osimertinib, AstraZeneca, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialTo Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations
Shares Osimertinib, AstraZeneca, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialOsimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib
Shares Osimertinib, AstraZeneca, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialDurvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation
Shares Osimertinib, AstraZeneca and the tag pipeline.
- TrialStudy of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours
Shares AstraZeneca, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialOleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study
Shares Osimertinib, AstraZeneca and the tag pipeline.
- TrialEfficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
Shares AstraZeneca, Metastatic cancer (cancer that has spread) and the tag pipeline.